Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 2114 of 6351
-
Could a common gene variant weaken bones early?
Knowledge-focused OngoingThis research study has two purposes. The first purpose is to determine whether having sickle cell trait (SCT) is a risk factor for the development of bone thinning at an earlier age than expected. Nearly 10% of African Americans (AA) carry sickle cell trait and most of them are …
Sponsor: UConn Health • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Turmeric compound tested to stop prostate cancer return
Disease control Recruiting nowThis is a prospective study to determine if the adjuvant use of Curcumin improves recurrence-free survival.
Phase 3 • Sponsor: yair lotan • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Ketamine's secret: family history of alcoholism may boost antidepressant effects
Knowledge-focused Recruiting nowA single subanesthetic dose infusion of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has rapid and robust antidepressant effects in patients with treatment-refractory major depressive disorder (TRD). A family history of an alcohol use disorder (Family History Posi…
Phase 2 • Sponsor: Mark Niciu • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
New cocktail targets tough lymphoma: carfilzomib joins R-ICE in early trial
Disease control OngoingThis phase I/Ib trial studies the side effects and best dose of carfilzomib when given together with rituximab, ifosfamide, carboplatin, and etoposide and to see how well it works in treating patients with stage I-IV diffuse large B-cell lymphoma that has returned (relapsed) or t…
Phase 1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New inhaler combo shows promise for Hard-to-Control asthma
Disease control CompletedPrimary objective The primary objective was to evaluate the efficacy of a free combination of CHF 5259 at 3 dose levels plus Foster® 100/6 μg in a pMDI by comparison with Foster® 100/6 μg in terms of forced expiratory volume in the first second (FEV1) area under the curve betwee…
Phase 2 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Singing together after stroke: a prescription for healing?
Symptom relief Recruiting nowThe study will focus on the impact of communal singing on patients with stroke and their personal caregivers. Forty post-stroke patients will be randomly assigned to two groups: the first group of 20 stroke survivors and their caregivers (up to 40 total participants) will receive…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Symptom relief
Last updated Jul 24, 2026 00:00 UTC
-
New checklist aims to slash MRSA infections in veterans after surgery
Disease control CompletedThe goals of this project are 1) to assess the effectiveness and cost-effectiveness of the checklist to prevent MRSA SSIs among Veterans undergoing TJA or cardiac surgery, and 2) to assess barriers and facilitators to checklist implementation. Hypotheses: 1. The SSI checklist w…
Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Knee pain relief without surgery? collagen injection shows promise
Symptom relief CompletedThe primary objective of this study is to confirm the superiority of intra-articular collagen injection in patients with knee joint pain compared to the control group. 100mm VAS is used to measure the pain of the subjects 24 weeks after the procedure.
Phase 4 • Sponsor: Cellontech Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
Can a 5-Day radiation course beat the standard for prostate cancer?
Disease control Recruiting nowPhase 1-2 study, comparing ultra-hypofractionnated (UH) to a moderately hypofractionnated (MH) radiation therapy, with image guided HDR prostate brachytherapy. Using iso-equivalent doses, a non-inferiority analysis will be done in order to prove UH non-inferior to MH, toxicity wi…
Sponsor: CHU de Quebec-Universite Laval • Aim: Disease control
Last updated Jun 26, 2026 14:45 UTC
-
Can a genetic test pick the best chemo for triple negative breast cancer?
Knowledge-focused CompletedThis is a phase II study randomizing patients with stage I with T1 \> 1.5 cm, stage II or III triple negative breast cancer (TNBC) to preoperative cisplatin versus paclitaxel. The study is designed to evaluate the ability of the Homologous Recombination Deficiency (HRD) assay to …
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Booster shot study aims to keep teens safe from whooping cough
Vaccine CompletedThis study is designed to assess the immunogenicity and safety of DTaP vaccine (BK1301) as a booster dose in adolescents. The purposes of this study are as follows: * To confirm the non-inferiority of BK1301 to Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid) with respec…
Phase 3 • Sponsor: Tanabe Pharma Corporation • Aim: Vaccine
Last updated Jun 27, 2026 08:08 UTC
-
Could an arthritis drug tame a tough transplant complication?
Disease control CompletedThe participant is invited to take part in this study because they have chronic Graft versus Host Disease (cGVHD) that is not responding to standard treatment with steroids. This research study is a way of gaining new knowledge about the treatment of patients with cGVHD. This res…
Phase 1/2 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis phase Ib/II trial studies the side effects and best dose of trametinib and navitoclax and how well they work in treating patients with solid tumors that have spread to other places in the body (advanced or metastatic). Trametinib may stop the growth of tumor cells by blockin…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New combo therapy shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis phase I trial studies the side effects and best dose of BTK inhibitor PCI-32765 when given together with rituximab and bendamustine hydrochloride in treating patients with recurrent non-Hodgkin lymphoma (NHL). BTK inhibitor PCI-32765 may stop the growth of cancer cells by bl…
Phase 1 • Sponsor: Kami Maddocks, MD • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug shows promise for stopping deadly seizures
Disease control CompletedThe purpose of this study is to evaluate the safety and tolerability of SAGE-547 in participants in super-refractory status epilepticus (SRSE).
Phase 1/2 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:02 UTC
-
Can a simple body scan safely check fluid levels in heart device patients?
Knowledge-focused CompletedThere are an increase number of patients with cardiac implantable electronic devices (CIEDs) such as pacemakers (PM) and implantable cardioverter-defibrillators (ICDs) worldwide. The current medical practice guidelines warn on performing bioimpedance analysis (BIA) in this group …
Phase 4 • Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
New radiation technique aims to save implants in breast cancer patients
Symptom relief CompletedThe purpose of this study is to determine if a radiation treatment called "Multi-beam Intensity Modulated Radiation Therapy"(IMRT) can reduce side effects related to your implant if they are a candidate for radiation therapy. Currently, the standard method of giving radiation is …
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
New vaccine strategy aims to shield spleenless adults from deadly infections
Vaccine CompletedEvaluate the immunogenicity of an innovative pneumococcal vaccination strategy in splenectomized adults comprising 1 dose of Prevenar13® conjugate vaccine (PCV) at M0 followed by 1 dose of Pneumo23® or Pneumovax® polysaccharide vaccine (PPSV) at M2. Duration of follow-up of 36 mo…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Vaccine
Last updated Jun 27, 2026 07:58 UTC
-
Experimental hepatitis b drug shows promise in early trial
Disease control Stopped earlyThe purpose of this study is to determine whether ARC-520 in combination with entecavir is effective in the treatment of patients with chronic HBV Infection.
Phase 2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Can a transition program keep young heart transplant patients on track?
Disease control CompletedThe purpose of this pilot trial, Transitioning to Adult Care (TRANSIT), is to develop and test an intervention (i.e., a standardized, tailored transition program focused on enhancing adherence) to improve outcomes for emerging adults who underwent heart transplantation as childre…
Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC